Context Therapeutics announced that on March 28, 2024, the Company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6-positive gynecologic and testicular cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results
- Context Therapeutics expects cash to fund operations into late 2024
- Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year
- Context Therapeutics, Inc. (CNTX) Q4 Earnings Cheat Sheet
- Context Therapeutics Unveils Updated Corporate Strategy Presentation
